Herpes Cure Research

Herpes Cure Researchers                 

        

                                                               

 
AddThis Social Bookmark Button
                                                                                

HOT NEWS ON CURE ! Updated August 5, 2012 

 
Free Singles Dating Site -

 
<script type="text/javascript">
    var infolink_pid = 373309;
    var infolink_wsid = 0;
</script>
<script type="text/javascript" src="http://resources.infolinks.com/js/infolinks_main.js" mce_src="http://resources.infolinks.com/js/infolinks_main.js"></script>
 
FIRST I WANT TO POINT OUT THERE IS NO COMPLETE CURE TO HERPES, IF YOU FIND A WEBSITE TRYING TO TELL YOU SO OR SELL YOU SOMETHING, NOT ONLY NOT BELIEVE THEM BUT REPORT THEM TO ME SO I CAN ADD THEM TO MY LIST OF FAKE SITES. HAVING SAID THAT LETS TALK ABOUT THE CURES SCIENTISTS AND COMPANIES ARE WORKING ON, I will only primarily publish news on cures although some info is on vaccines & treatments, which may lead to cures. Note: I ranked in order of my proposed expected release date in parenthesis(remember most of these will fail and things could change to bump up expected release dates) I put a "*" by the company updated last:
 
If you would like to join our EMAIL list fill out form below and click subscribe:
***Email list will also include you into a stock picker website. 
 

 

<!-- Begin MailChimp Signup Form -->

<link href="http://cdn-images.mailchimp.com/embedcode/slim-081711.css" rel="stylesheet" type="text/css">
<style type="text/css">
#mc_embed_signup{background:#fff; clear:left; font:14px Helvetica,Arial,sans-serif; }
/* Add your own MailChimp form style overrides in your site stylesheet or in this style block.
  We recommend moving this block and the preceding CSS link to the HEAD of your HTML file. */
</style>
<div id="mc_embed_signup">
<form action="http://webs.us5.list-manage.com/subscribe/post?u=1a672152823054bb1d58c74d3&amp;id=adee0fa7be" method="post" id="mc-embedded-subscribe-form" name="mc-embedded-subscribe-form" class="validate" target="_blank">
<label for="mce-EMAIL">Subscribe to our mailing list</label>
<input type="email" value="" name="EMAIL" class="email" id="mce-EMAIL" placeholder="email address" required>
<div class="clear"><input type="submit" value="Subscribe" name="subscribe" id="mc-embedded-subscribe" class="button"></div>
</form>
</div>

<!--End mc_embed_signup-->
<!-- Begin MailChimp Signup Form -->
<div id="mc_embed_signup">
<form action="http://webs.us5.list-manage2.com/subscribe/post?u=1a672152823054bb1d58c74d3&amp;id=adee0fa7be" method="post" id="mc-embedded-subscribe-form" name="mc-embedded-subscribe-form" class="validate" target="_blank">
<h2>Subscribe to our mailing list</h2>
<div class="indicates-required"><span class="asterisk">*</span> indicates required</div>
<div class="mc-field-group">
<label for="mce-EMAIL">Email Address  <span class="asterisk">*</span>
</label>
<input type="email" value="" name="EMAIL" class="required email" id="mce-EMAIL">
</div>
<div class="mc-field-group input-group">
    <strong>Email Format </strong>
    <ul><li><input type="radio" value="html" name="EMAILTYPE" id="mce-EMAILTYPE-0"><label for="mce-EMAILTYPE-0">html</label></li>
<li><input type="radio" value="text" name="EMAILTYPE" id="mce-EMAILTYPE-1"><label for="mce-EMAILTYPE-1">text</label></li>
<li><input type="radio" value="mobile" name="EMAILTYPE" id="mce-EMAILTYPE-2"><label for="mce-EMAILTYPE-2">mobile</label></li>
</ul>
</div>
<div id="mce-responses" class="clear">
<div class="response" id="mce-error-response" style="display:none"></div>
<div class="response" id="mce-success-response" style="display:none"></div>
</div> <div class="clear"><input type="submit" value="Subscribe" name="subscribe" id="mc-embedded-subscribe" class="button"></div>
</form>
</div>

<!--End mc_embed_signup-->
<!-- Begin MailChimp Signup Form -->
<link href="http://cdn-images.mailchimp.com/embedcode/slim-081711.css" rel="stylesheet" type="text/css">
<style type="text/css">
#mc_embed_signup{background:#fff; clear:left; font:14px Helvetica,Arial,sans-serif; }
/* Add your own MailChimp form style overrides in your site stylesheet or in this style block.
  We recommend moving this block and the preceding CSS link to the HEAD of your HTML file. */
</style>
<div id="mc_embed_signup">
<form action="http://webs.us5.list-manage.com/subscribe/post?u=1a672152823054bb1d58c74d3&amp;id=adee0fa7be" method="post" id="mc-embedded-subscribe-form" name="mc-embedded-subscribe-form" class="validate" target="_blank">
<label for="mce-EMAIL">Subscribe to our mailing list</label>
<input type="email" value="" name="EMAIL" class="email" id="mce-EMAIL" placeholder="email address" required>
<div class="clear"><input type="submit" value="Subscribe" name="subscribe" id="mc-embedded-subscribe" class="button"></div>
</form>
</div>

<!--End mc_embed_signup-->
 
I WILL PUT UPDATES OF THE LAST 3 MONTHS (WHEN I CAN) 
MAY, JUNE, JULY   2012    UPDATES : #2, #10, #12, #14
 

 

                
I HAVE MADE THOUSANDS, SINCERELY WALLY DAMRON WEBSITE OWNER & CLICKBANK MEMBER 
 
 
1. Fraunhofer Institute for Interfacial Engineering & Biotechnology IGB(3D herpes infection model, HSV-1)(2011, BEING PERFECTED): To me personally this is the best news of the year. This is new technology which may speed up the process of finding a cure since they claim their research will aid in the testing of future cold sore treatments by reducing the need for animal testing. The latest news I have on this is dated June 8, 2011 :http://medgadget.com/2011/06/fraunhofer-develops-3d-herpes-model-to-test-potential-treatments.html , June 28, 2011: http://news.bioscholar.com/2011/06/first-3d-herpes-infection-model-promises-new-treatment-for-cold-sores.html
  

 

2.  StarPharma (Vivagel, HSV-2)(2013) –I think most people will agree based on enormous evidence that this drug will probably be one of the first to come out(in the form of a condom coating), Vivagel is a preventive gel intended for women to help protect them from getting the genital hsv infection, Vivagel apparently is a topical gel applied to the vaginal area which is suppose to kill herpe’s on contact. It has been rumored that a deal between StarPharma & Durex has been made to coat their condoms with Vivagel. And it may be released in the near future in Japan with an agreement with Okamoto another condom maker. Vivagel is in phase II development with the FDA, but I will point out that Japan is not bound by FDA regulations.  Latest news was May 23, 2011 : http://starpharma.com/news/68 , Update**Starpharma  Gets FDA approval for Phase III study,  its primary focus will be for BV instead of hsv, I assume to bring it to market quicker, expected to start in early 2012 and end in about 1 year afterwards. Latest news March 22, 2012 : http://www.starpharma.com/news/113 . March 26, 2012 : http://www.brrmedia.com/event/81263 , June 4, 2012 :*** PHASE III IN PROGRESS http://www.starpharma.com/news/118, June 25, 2012 : 

http://www.starpharma.com/news/120

 

 

 

 

 3. BioAllance Pharma(Sitavir, Oral HSV)(2013):  Is working on a product intended for cold sores which combines acyclovir &  lauriad(a drug they have developed) claims as a one tablet only at the first signs of a cold sore will be all you need everytime a cold sore develops. This is very promising, since the savings you would have by only taking one pill for the majority of people who have less than 6 outbreaks a year which would mean theoretically taking 6 or less pills a year.  September 21, 2011: http://www.news-medical.net/news/20100826/FDA-notification-confirms-acyclovir-Lauriad-for-oro-facial-herpes-labialis.aspx , Looks like Phase III trial is complete and they have submitted it for FDA and European approval October 5, 2011 :  

 

 

 

4. Chimerix (CMX001, HSV-1 & 2)(2015)- Is an anti-viral which is derived from the currently used drug Cidofovir(an injectible), its main advantage seems to be that for one it is intended to be an oral drug and is not suppose to be as toxic. Tests in animal studies have revealed it may be up to 250 times stronger than Cidofovir without as many dangerous side effects, the main question is if it is released will it be used for HSV. They are currently in Phase II studies, other promising news is that they received a $36.1 million grant for their research from the NIH. Latest news was April 15, 2011: http://www.chimerix-inc.com/news-and-resources/news-and-resources-details/needham-and-future-leaders/ , CMX001 Granted fast track status.  July 13, 2011: http://www.chimerix-inc.com/news-and-resources/news-and-resources-details/chimerix-commences-phase-2-clinical-study-of-cmx001-for-prevention-of-adv , July 22, 2011 : http://www.infocastinc.com/index.php/conference/biodef11 , September, 2011: CMX001 Being used as investigational drug for terminally ill patients including ones who have HSV-1 & 2.

 

  
5. AICURIS (AIC-316, HSV-2)(2015)- AIC-316, intended for HSV2 is suppose to be a therapeutic drug that is suppose to greatly reduce all viral shedding and could prevent the transmission to others, possibly making it close to a permanent suppression drug.. UPDATE ** Aicuris releases results on phase II study(and appears to be successful, I personally think they will probably enter a Phase III study in the near future, and should be able to obtain partners if they can’t get the financing themselves), July 18, 2011 :http://www.aicuris.com/index.php/fuseaction/download/lrn_file/20110718-press-release-aic316-phase-ii-en-final.pdf    April 16, 2012 : http://www.b3cnewswire.com/20120807750/aicuris-promising-drugs-against-herpes-simplex-aic316-and-human-cytomegalovirus-letermovir-aic246-in-preparation-for-phase-iii.html

 

6. GlaxoSmithKline (NanoBio(NB-001), HSV-1)(2015): The makers of Abreeva recently bought out one company(I can’t remember the name of that company) that  was to compete with abreeva and entered an agreement partnership with NanoBio to help bring it into Phase III trials. It is a topical ointment. I presume this will be an over-the-counter treatment for cold sores. Latest information I have unknown date, http://www.nanobio.com/Dermatology/Herpes-Labialis.html

 

7. PEREGRINE (Bavituximab, HSV-1 & 2?)(2018) : Currently in Phase II clinical development against Certain Cancers, bavituximab is the first in a new class of patented antibodies that target and bind to the cellular membrane component phosphatidylserine (PS). PS is a highly immunosuppressive molecule usually located inside cells, but which becomes exposed on the outside of the membranes of certain viruses and virally infected cells, creating a target for antiviral therapy. There has been some belief that this is a wide spectrum drug and could be used to treat many virus’s including the Herpe’s strains of virus’s, more in particularly CMV, but some scientists suggest it could cure HSV by eliminating the sensory neurons. Now whether this would be good on the body I do not really know. The latest news I have on this is April 1, 2011: http://docs.google.com/viewer?a=v&q=...8lUOq60A&pli=1

 

 

 


 
 
8. AGENUS (HerpV, HSV)(2018) – HerpV also known as AG-707 is an interesting vaccine intended for HSV2 where that it attacks the virus by producing more CD4 and CD8 Killer T cells. What I like about this vaccine is that it is definitely unique in how it operates, it could potentially cure HSV. It also had (although small) a very successful Phase I study. Its major obstacle is funding it seems, I almost have to think they will have to get a larger pharmaceutical company to back them up. Their financials are not very good. But things could turn around quickly if they get someone to back them up or possibly grant funding for their research. The latest news I have on them is July 27,2010 :http://www.agenusbio.com/docs/herpv/0727.pdf
 , Spetember 26, 2011 
http://www.agenusbio.com/docs/pr/2011/0926.pdf  , December 2011 : Agenus plans on Phase II sometime in 2012, 
 
 

 

 


9. Beech Tree Labs (BTL-TML-HSV, HSV-1 & 2)(2018) - In vitro work conducted by company scientists has show results suggesting that this product inhibits re-assembly of virus particles after infection of cells and virus uncoating. Confirmatory work has yet to be completed. On-going genomics studies are revealing mechanism of action. Looks to be a wide spectrum Herpes anti-viral. Apparantly 2 separate trials seem to be going on as we speak, a Phase I and Phase IIa , I know of which one is for oral HSV, latest news I have is dated Spetember 16, 2010:  http://www.bioportfolio.com/news/pdf/270814/Beech-Tree-Labs-Closes-Financing-Two-Fda-authorized-Clinical-Trials-In-Progress.pdf, September 15, 2011 HC member XIPPIN received email from Beech Tree - Beech trees product blocks the uncoating of the virus so that virus DNA can't be synthesized within the infected cell. As a comparison, aic-316 uses a method of helicase-primase inhibition, which binds to segments of the virus and prevents viral operation. Phase I/IIa is scheduled to be done this fall. Schedule for further phases is dependent on phase I results. September 22, 20011: Patent filedAn interesting suggesting it may use ethyl mercury 

http://www.faqs.org/patents/app/20110230554

 

   

 

  note: it is utilized by sublingual (under the tongue) drops. They also stated if effective for HSV-1 then use for HSV-2 should follow. January 2012 , Trial expected to end June 2012 : http://clinicaltrials.gov/show/NCT01308424  

 

 

10. Genocea (GEN-003, HSV-2)(2019)- Genocea is developing both therapeutic and prophylactic vaccines for HSV-2 based on the discovery of antigens with its technology. In in vivo preclinical proof-of-concept studies, the antigens have demonstrated protection against disease, reduced viral shedding and lesion recurrence. Although their HSV2 vaccine is still preclinical they recently received $35 million dollars in financing and have partnered with several companies. I rate Genocea higher than some others since it appears from all the drugs they are working on, HSV is their primary focus. Latest news was on Veryy interesting conference March 2012 : http://www.terrapinn.com/conference/world-vaccine-congress-washington/presentation-2011-the-next-generation-of-hsv2-vaccine-development-directing-the-immune-response-by-antigen-selection-and-combination-with-(ABR)-101730.stm
 ,                                                                                                               
 
May 04,2012: 
http://www.businesswire.com/news/home/20120504005135/en/Genocea-Highlights-Key-Progress-Development-Vaccine-Candidate , August 5, 2012: http://www.marketwatch.com/story/genocea-unveils-protective-therapeutic-vaccine-for-herpes-simplex-virus-type-2-hsv-2-2012-08-05

 

 
 
 
11. Coridon Pty Ltd, Dr. IAN FRAZIER(HSV-2)(2019) : The founder of the HPV vaccine made Australian of the year for this work. Has a strong interest in HSV research. Will be head of a new research facility, the largest in Australia, He will have a lot of funds and people at his disposal, now whether or not he will utilize it for HSV research remains to be seen. Update, Ian Frazier and his team are working on HSV2 research. June 24, 2011, HC member Helpiamconfused2 received email from Coridon : “a planned Phase I trial is expected in early 2012, 1. Can you tell me the aim of your therapeutic vaccine? Complete suppression, cure, or what? IF IT WORKS IT SHOULD BE A CURE.
2. How have results in animal trials fared re the same and viral shedding, etc? OUR ANIMAL RESULTS WILL BE PRESENTED AT THE 5TH VACCINE AND ISV ANNUAL GLOBAL CONGRESS IN OCTOBER IN SEATTLE.
3. Are you accepting investors? OUR MAJOR INVESTOR BIOMD (ASX:BOD) IS A LISTED COMPANY ON THE AUSTRALIAN STOCK EXCHANGE.
4. Will your clinical trials be in the US? OUR INITIAL TRIALS WILL BE IN AUSTRALIA. ONCE WE HAVE PROOF OF THE VACCINE WORKING, WE WILL THEN LOOK TO THE USA.” , February 17, 2011 :http://www.lifescientist.com.au/article/376895/feature_dna_vaccine_vanguard/ , date unknown :http://www.coridon.com/page/current_development_program.html August 21, 2011: HC member Rational Response stated that received email and that there first trials will be focused on preventive only. .. October 9, 2011, Coridon partners with Allied HealthCare and reports 100% effective vaccine for those not previously infected in animals: http://www.news-medical.net/news/20111010/Coridon-demonstrates-10025-protection-using-DNA-HSV-2-vaccine.aspx
 
 
12. VICAL (HSV-2)(2020) – Another one of my favorite companies, they seem to release news almost weekly lately. Their HSV2 vaccine is intended for already infected individuals to be a permanent suppression and to work on individuals who are not infected. They have two patents, which leads me to believe they may be working on two different variations of the drug. Although it is in pre-clinical trials, Vical has a lot of money to spend, has no debt and is aggressively seeking partners and has succeeded in obtaining them on most of their other drugs in development. They recently hinted that HSV2 was probably going to be their primary focus after they finish their cancer drug and CMV drug(received up to $130 million investment to finish phase III) which are both almost finished and also leaked out that they we’re in discussions with partners on their HSV2 vaccine. Said recently in February 2012 , that a Phase I human trial most likely later this year or in 2013. Their latest news came on July 14, 2011 : http://www.vical.com/investors/events-presentations/Event-Details/2011/dna-vaccines-conference-2011/default.aspx , Date unknown probably sometime in July 2011:http://www.vical.com/Theme/Vical/files/doc_downloads//The%20Simplex%20Solution%20110721.pdf , Aug 3,2011: Complete conference call transcript: http://seekingalpha.com/article/284406-vical-s-ceo-discusses-q2-2011-results-earnings-call-transcript , February 29, 2012Conference: http://www.wsw.com/webcast/canaccord4/vicl/ 
  , May 2, 2012 : Planned Planned combined Phase 1 & 2 Trial : http://www.vical.com/investors/news-releases/News-Release-Details/2012/Vical-Reports-First-Quarter-2012-Financial-Results-and-Progress-in-Key-Development-Programs1129246/default.aspx
 JULY 12, 2012 : Phase 1/2  trial to possibly start in 12 months : http://wsw.com/webcast/jmp18/vicl/

 

13. Sanofi Pasteur & Dr. Knipe (Acam-529, HSV-2)(2020):  It is intended for HSV2. What’s interestingabout this Vaccine is that it is the only Live HSV vaccine that is scheduled for a phase I study in 2012 in various news reports. Another promising thing about this drug is that how the closest relative to HSV, VZV is vaccinated with a live vaccine. What I find interesting in the news articles is that there is a lot of talk about Africa and its high rate of HSV and HIV contained in every article I can find that mention’s Sanofi’s planned Phase I study, I think they may be planning a large Phase I study in Africa. I think the drug is intended to be both a vaccine for infected as well as un-infected individuals. Sanofi is a huge company and has almost unlimited resources to push this drug through quickly if it works. Looks like a planned conference is scheduled around August 17, 2011 to discuss more about Acam-529: http://www.the-infoshop.com/conference/imvacs11/vac2.shtml

 

8. AMGEN (Immunovex2, HSV-2)(2019) – Recently purchased by Amgen from Biovex, Immunovex2 is intended as both therapeutic and preventive vaccine for HSV2. A Phase I study was started in February 2010, but completion and/or results are unknown. The bad news is that AMGEN bought Biovex mainly for its cancer drug, the good news is that AMGEN recently acknowledged the existence of Immunovex2 and briefly discussed it, sort of implying they are working on it. Also AMGEN has the money to back up any research study if it chooses to do so. The latest news was on March 7,2011(you will have to register to listen to this conference((it mentions and I quote “"It is interesting that we are able to remove two of the Herpes Simplex proteins".)) )http://www.wsw.com/webcast/cowen3/register.aspx?conf=cowen3&page=amgn&url=http%3A//www.wsw.com/webcast/cowen3/amgn/ , August 6, 2011: HC member JAY9876 stated “I spoke to the co-founder of Biovex, Robert Coffin, about 6 weeks ago and he mentioned phase II trials should begin around February/March 2012.”. AGENUS (HerpV, HSV-2)(2018) – HerpV also known as AG-707 is an interesting vaccine intended for HSV2 where that it attacks the virus by producing more CD4 and CD8 Killer T cells. What I like about this vaccine is that it is definitely unique in how it operates, it could potentially cure HSV. It also had (although small) a very successful Phase I study. Its major obstacle is funding it seems, I almost have to think they will have to get a larger pharmaceutical company to back them up. Their financials are not very good. But things could turn around quickly if they get someone to back them up or possibly grant funding for their research. The latest news I have on them is July 27,2010 : http://www.agenusbio.com/docs/herpv/0727.pdf ,June 27,2011 :http://www.agenusbio.com/docs/pr/2011/0627.pdf , UPDATE ** Rumored they are trying to get backing for Phase II study July 14, 2011: http://www.herpessymptoms-inmen.com/http:/www.herpessymptoms-inmen.com/is-a-vaccine-for-genital-herpes-just-around-the-corner/ , Update Planned Phase II suspected for HerpV mid 2012 September 26, 2011: http://www.proactiveinvestors.com/companies/news/18832/agenus-reports-positive-results-for-its-herpv-drug-18832.html

 

AMGEN (Immunovex2, HSV-2)(2019) – Recently purchased by Amgen from Biovex, Immunovex2 is intended as both therapeutic and preventive vaccine for HSV2. A Phase I study was started in February 2010, but completion and/or results are unknown. The bad news is that AMGEN bought Biovex mainly for its cancer drug, the good news is that AMGEN recently acknowledged the existence of Immunovex2 and briefly discussed it, sort of implying they are working on it. Also AMGEN has the money to back up any research study if it chooses to do so. The latest news was on March 7,2011(you will have to register to listen to this conference((it mentions and I quote “"It is interesting that we are able to remove two of the Herpes Simplex proteins".)) )http://www.wsw.com/webcast/cowen3/register.aspx?conf=cowen3&page=amgn&url=http%3A//www.wsw.com/webcast/cowen3/amgn/ , August 6, 2011: HC member JAY9876 stated “I spoke to the co-founder of Biovex, Robert Coffin, about 6 weeks ago and he mentioned phase II trials should begin around February/March 2012.”. AGENUS (HerpV, HSV-2)(2018) – HerpV also known as AG-707 is an interesting vaccine intended for HSV2 where that it attacks the virus by producing more CD4 and CD8 Killer T cells. What I like about this vaccine is that it is definitely unique in how it operates, it could potentially cure HSV. It also had (although small) a very successful Phase I study. Its major obstacle is funding it seems, I almost have to think they will have to get a larger pharmaceutical company to back them up. Their financials are not very good. But things could turn around quickly if they get someone to back them up or possibly grant funding for their research. The latest news I have on them is July 27,2010 : http://www.agenusbio.com/docs/herpv/0727.pdf ,June 27,2011 :http://www.agenusbio.com/docs/pr/2011/0627.pdf , UPDATE ** Rumored they are trying to get backing for Phase II study July 14, 2011: http://www.herpessymptoms-inmen.com/http:/www.herpessymptoms-inmen.com/is-a-vaccine-for-genital-herpes-just-around-the-corner/ , Update Planned Phase II suspected for HerpV mid 2012 September 26, 2011: http://www.proactiveinvestors.com/companies/news/18832/agenus-reports-positive-results-for-its-herpv-drug-18832.html

 14

. AMGEN (Immunovex2, HSV-2)(2020) – Recently purchased by Amgen from Biovex, Immunovex2 is intended as both therapeutic and preventive vaccine for HSV2. A Phase I study was started in February 2010, but completion and/or results are unknown. The bad news is that AMGEN bought Biovex mainly for its cancer drug, the good news is that AMGEN recently acknowledged the existence of Immunovex2 and briefly discussed it, sort of implying they are working on it. Also AMGEN has the money to back up any research study if it chooses to do so. The latest news was on March 7,2011(you will have to register to listen to this conference((it mentions and I quote “"It is interesting that we are able to remove two of the Herpes Simplex proteins".)) ) :http://www.wsw.com/webcast/cowen3/register.aspx?conf=cowen3&page=amgn&url=http%3A//www.wsw.com/webcast/cowen3/amgn/ , June 18, 2012 : rumored .. Phase I study was completed in February 2012 and results were that drug was well tolerated and ready for a Phase II study and this has both theand prophylactic properties. , 07/14/2012 : Anonymous reliable source said he went to the doctor who help design the trial for Immunovex stated that it did not work.              

 

 

 

 

 15
 Gilead Sciences (CAPRISA 004, FACTS 001, FACTS 002 & VOICE, HSV-2, Prophylactic for women)(2021 ?) – This is the name(s) of a clinical trial *** SUSPENDED ***** that is being done in Africa and is expected to start a Phase III study in July, 2011, involving  2,200 women, FACTS001 involves 18-30 year old women & FACTS002  involves a smaller group within the 2,200 women of 16-17 year olds, and is expected to last 24 months. ** UPDATE : VOICE study may be replacing FACTS studies, it involves 5,000 women and is expected to end in early 2013 as FDA has awarded fast track designation. **This is a Vaginal Gel intended for women to help prevent the risk of HIV and HSV Infection. Although it initially was planned for HIV protection only, they have expanded it and acknowledged it will be used for both HSV & HIV, it was found in a phase IIb study to be effective in both with a 39% reduction in HIV infection and a 51% reduction in HSV infection.  This could theoretically put it ahead of Vivagel when you consider it is not to be intended as a condom coating. It is a microbicide containing 1% tenofovir in the gel form. To learn more you can go to:http://en.wikipedia.org/wiki/CAPRISA_004 , the latest news I have on this is dated June 20,2011 :http://www.eurekalert.org/pub_releases/2011-06/c-agl062011.php , July 18, 2011 mostly mentions hiv prevention, but briefly hsv : http://blog.aids.gov/2011/07/scientific-advances-and-the-fight-against-aids.html ,  Granted Fast track status , October 27, 2011 : http://www.aidsmap.com/FDA-will-give-fast-track-to-tenofovir-gel-approval/page/1526154/, NOVEMBER 28, 2011: Phase III trial has been suspended due to ineffectiveness against HIV, U of W is conducting a small human trial involving 55 people sometime in 2012, I will specualte that maybe they are looking at GHSV-2.

 

 

 

16. SIMPLEXIA (HSV-2)(2021) – They are working on a protein based vaccine for HSV-2, I am not quite sure yet if this is only intended for pre-infected persons or newly infected. They recently received a grant in 2011. Latest news I have is dated November 23, 2011:  

 

17. NANOVIRICIDES (HSV-1 & 2)(2021): Is an anti-viral Topical ointment as well as possibly a pill. Has been shown in studies to kill the HSV virus and has the potential of possibly killing the virus permanently. Not a lot is known about its action. This is suppose to be a wide spectrum anti-viral due to my understanding. HC member Sweet7 gave this description: ” The drug is basically like fake human cells. These cells are very attractive to viruses. Once a virus attaches itself to one of these cells, the cell begins to basically attack the virus. It completely covers it and destroys the membrane of the virus and the capsids fall out of the viral membrane. The viral capsids have no way of attaching to cells, have no protein coat to hide from the immune system, and are non-infectious. Capsids are what delivers the viral dna to cells, so Nanoviricide cells literally destroy the virus. What I don’t know is if these cells can attract the virus well enough to come out of the neuron, or if they are small enough to enter a neuron. I have to admit, I really like the theory behind this, but they really need to get this in a pill form, or figure out another way to vectorize these cells.” They are rumored to be working on bringing a study involving humans in Africa, it is unclear whether it is intended for HIV, HSV or both or something else. The latest news I have on this anti-viral is August 10,2009: http://www.news-medical.net/news/20090810/Nanoviricides-anti-herpes-drug-candidate-reduces-viral-load-by-999925.aspx , June 23, 2011 :http://www.proactiveinvestors.co.uk/companies/news/29769/nanoviricides-to-present-at-`onemedforum-conference-in-new-york-city-29769.html

 

 

18.  Stem Cell Therapy(HSV-1 & 2)(2021): New stem cell therapy could hold the key to future treatment of HIV and possibly Herpes viruses according to Professor Ben Berkhout from the University of Amsterdam.
Speaking at the Spring conference of the Society for General Microbiology, Prof. Berkhout explained that anti-retroviral drug administration commonly used in the treatment of HIV has limited effectiveness due to a low patient compliance rate as well as the virus’s ability to mutate – leading to drug-resistant strains which are difficult to treat.
By extracting and treating stem cells, the antiviral DNA can theoretically be delivered directly to the patient’s auto-immune system, bypassing drug administration. Cells would be taken from the patient’s bone marrow, and treated with anti-viral DNA in vitro, after which the stem cells would be re-injected into the patient.
Prof. Berkhout explains: “Stem cells are the continually dividing ‘master copy’ cells from which all other immune cells are derived.” By engineering the stem cells, the antiviral DNA is inherited by all the immune cells that are born from it.”
Prof. Berkhout envisages commencing laboratory tests within three years, saying: “So far, very promising results have been obtained in the laboratory, and we are now testing the safety and efficacy in a pre-clinical mouse model.” Latest news September 2011: http://en.wikipedia.org/wiki/Stem_cell_treatments

 

19. CELLECTICS (HSV1)(2022) : Don’t know much about this one, it uses a technique called virus clipping also known as meganucleases, it is suppose to be a cure. I do not know its mode of delivery but suspect it’s a vaccine. The good news is this seems to be a pretty good financially sound company and I believe they have the money to back up any research. The latest news I have on this drug is dated January 19, 2011:http://www.cellectis.com/sites/default/files/110119_MolecularTherapy_EN_0.pdf, June 29,2011 Cellectics & a company called Pregenen are working together now with meganucleases:http://www.cellectis.com/media/press-release/2011/cellectis-and-pregenen-sign-collaboration-agreement-development-meganucleas

 

20.  GenVec (HSV-2)(2022): Taken directly from their website: We are developing vaccines for the prevention and treatment of HSV-2, the virus responsible for most cases of genital herpes. In the United States, HSV-2 infects some 1.6 million new people per year, with approximately 500,000 of those suffering from disease symptoms. At least 40 million people in the United States are infected with HSV-2. Even higher infection rates are evident in developing countries, with further complications in people also infected with HIV. All HSV-2 infections are permanent and result in periodic virus shedding. There is no approved vaccine for HSV-2. Although antiviral regimens have become a standard of care, their inconvenience, cumulative cost and potential for drug resistance further underscore the need for safe, new approaches to reducing HSV-2 lesions, shedding, and transmission. Estimated costs of treating HSV-2 in the United States alone are close to $1 billion, primarily for drugs and outpatient medical care. Latest news I have is date March 3, 2008 about a grant they received:http://www.biospace.com/news_story.aspx?NewsEntityId=88428 , Conference call discussing in part about HSV-2, August 9, 2011: http://webcastingplayer.corporate-ir.net/player/playerHOST.aspx?c=124130&EventId=4157737&StreamId= 1710768&TIK={55691ada-f745-4404-a457-f478ebd58bee}&RGS=3&IndexId=

 

 

21. Novotech, Marine Biotechnology Australia Pty Ltd(HSV-1 & 2)(2022)- This is a company working on a drug that is suppose to be a better treatment for the Herpes Simplex Virus & Shingles. Whats interesting about this company is that the drug they are working on comes from a chemical found in Sea Snails. They recently received 1.2 million dollar grant to fund their research. Th latest news I have is dated June 15, 2011:http://www.novotechmediaroom.com/2011/herpes-zoster-novel-treatment-hope-from-tasmanian-abalone-gets-1-2-million-boost/


22. MIT (Draco, HSV-1 & 2)(2022) : They are working on a drug called Draco, which in theory could cure all diseases, said it wouldn’t be available probably for at least 10 years, I will speculate that if its as good as they are saying several major pharmaceutical companies are probably looking at it. Latest news I have is dated August 13, 2011: http://www.ibtimes.com/articles/197337/20110813/new-drug-cure-any-viral-infection-mit-scientists-draco.htm, August 10, 2011: http://www.prohealth.com/library/showarticle.cfm?libid=16451Complete Research article ! May, 2011: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0022572

23. Dr. CULLEN & Dr. BLOOM(HSV-1 & 2)(2022) : They we’re working on a study with rabbits for HSV2 research, and were suppose to be finished in February 2011, but have yet to post any info, led by bloom. They are now seemingly working on HSV1. But have never released any findings on either. These people have been working either together or separately since 1999. Maybe more funding would help them or a partner, wonder what might be scaring partners away (if that is the case). This is the latest research I have on them dated January 12,2011: http://www.herpescureresearch.org/jan-12-2011.htm March 7, 2011 :http://www.herpescureresearch.org/mar-07-2011.htm , HC Member Helpiamconfused2 stated he received an email that June 17,2011 they will know if they will receive a grant from the NIH. June 22, 2011 : Grant received $250,000/yr for 5 years starting in December 2011.

 

24.  Fred Hutchinson Cancer Center, University of Washington, Dr. Keith Jerome(HSV-2)(2023) : Keith Jerome's work on homing mega- endonucleases - he just got a large grant to do this for HIV, but planning to apply for HSV-2 as well. Latest news I have undated bio : http://depts.washington.edu/micro/faculty/jerome.htm

 

25. Makerere University (Zinc Finger Technology, HSV-2)(2023): *UPDATE- Could be possible CURE, Funding is the hurdle for now*  . Is a brand new technology, being studied for HSV2, that claims it will Disrupt of over 60% of the infected cell's DNA, which would represent a cure as the elements disrupted are vital to viral replication. Viral vector using replication defective HSV vector would deliver ZFN to spinal ganglia. The good news is that this may be the way of the future for curing diseases, the bad news is that its so new it has not even reached pre-clinical phase and thus, unless major funding is provided, it will be a very long time before you see anything become of this if it works. The latest news I have is dated June 24, 2011:http://www.tbiomed.com/content/pdf/1742-4682-8-23.pdf , http://www.restrizymes.net/
 
 
 
 26
. MYMETICS (HSV1 & HSV2)(2024): a Vaccine in early stages of development, this is taken directly from their website; Exploratory experiments were performed on mice in which the immunogenicity of HSV-1 virosomes is investigated, following injections through various routes (intra-muscular and intra-nasal).

The next stage of research will focus on the development of new virosomes. If results are confirmed, up-scale and GMP production will be investigated with mandatory toxicity evaluation in animals. A small Phase I clinical trial in a population of seronegative subjects to HSV to assess the safety and tolerability of the vaccine should take place soon after toxicology studies. The latest news I have on them is dated April 5, 2011 :http://www.swissequitybiotechday.ch/media/biotech%20day%202011/pr%C3%A4sentationen/mymetics.pdf

 

27. Harvard Medical School (HSV-2)(2024) – They are working on a topical treatment in which was shown in mice to wipe out the disease when first diagnosed it uses RNAi to develop key genes to wipe out the transmission of the herpes virus, they have received a grant from both the Massachusetts Life Center & another grant from the NIH(although for HIV). The latest news I have is dated  ,January 21, 2009:http://news.harvard.edu/gazette/story/2009/01/topical-treatment-wipes-out-herpes-with-rnai/ ,  although HC member HOPEFILLED said “they received a patent on this on May 17, 2011. Patent #7,943,589”.

 

28. Dr. William Halford(HSV-1 & 2)(2024) : He is working on a Live vaccine intended for HSV1, but says it will probably work for HSV2 as well. A study involving mice with a lethal dose of HSV1 showed that after 30 days mice that we’re previously vaccinated showed no signs of HSV infection. The good news is it looks like it may work and its interesting that he is the only other person I know of working on a live hsv vaccine, the bad news I think is funding, not much has happened as of late with his work that I know of. The latest news I have on this is dated January 26, 2010 :http://media.www.alestlelive.com/media/storage/paper351/news/2010/01/26/News/Siu-Professor.Finds.Possible.Cure.For.Herpes-3857471.shtml

 

 

 

 

29. CEL-SCI (HSV)(2025): A Vaccine that uses peptide immunogens to get a better immune response also involves the C4 T cells. This is in early preclinical trials. Seems like it would target all family of Herpe’s virus’s. Latest news was June 5, 2009: http://www.bizjournals.com/baltimore/stories/2009/06/01/daily63.html

 



30. ALPHAVAX (HSV-2)(2025) – This comes directly from their website: AlphaVax is developing prophylactic and therapeutic alphavaccine products focused on the sexually transmitted form of HSV. These products are leveraged by 6 years of preclinical work showing excellent prophylactic protection in animal models as well as the ability to reduce HSV reactivation and disease severity in state-of-the-art therapeutic disease models. A successful prophylactic vaccine product is expected to require the induction of both antibody and T-cells, which makes HSV an ideally suited target for our alphavaccine platform. Based on successful preclinical work which is now published, AlphaVax is advancing an HSV alphavaccine into clinical testing early in 2010. Following phase 1 safety and immunogenicity trials, a phase 2 proof-of-concept trial may be carried out in "discordant couples" which should provide an early indication of efficacy. I’m not sure what the holdup on taking this to trials, but suspect it is money, they are currently looking for partners. The latest news I have on this vaccine is dated November 4, 2009: http://www.alphavax.com/docs/pr/release_59.pdf

 


31. Biomedical Research Models (HSV2)(2025): Currently working on a vaccine for HSV2, received a nice large grant for their research. Not much known about this company. Latest news I have is dated February 23, 2009 :http://www.biomere.com/pdf/2009-grant-press-1.pdf
 
32. Juvaris Biothermatics (HSV-2)(2028): Juvaris is developing a novel proprietary adjuvanted prophylactic HSV-2 vaccine employing multiple antigenic constructs. HSV-2 is a member of the herpesvirus family, and is the leading cause of genital herpes. In the US, approximately 50 million people (20%-30%) have genital herpes infection and new infections occur at a rate of approximately one million per year. HSV-2 infections are chronic and result in viral shedding in both symptomatic and asymptomatic individuals. Antiviral regimens have become a standard of care in the treatment of the HSV-2 infection. The necessity for daily administration and the high cost during the lifetime of the patient exemplifies the need for alternative preventative methods for reduction of HSV-2 viral shedding and transmission to uninfected individuals. HSV-2 positive individuals are also at a five-fold higher risk of contracting HIV versus those that are uninfected. A JVRS-100 adjuvanted vaccine has demonstrated substantial and long-term protection in the guinea pig HSV-2 infection model, the established standard for assessing pre-clinical efficacy. Latest news dated (2008?) pipeline:http://www.juvaris.com/pipeline/vaccines.html

33. VIRONOVA (VN-180)(2028) - Therapeutic Antiviral - Vironova’s lead compound, VN-180, is a CAI which acts to block the formation of the virus particle, thus inhibiting newly replicated viruses from maturing and becoming infectious. This unique broad range Herpes antiviral has been developed significantly faster than industry average utilizing Vironova’s virus analysis technologies. VN-180 has been presented to major pharmaceutical companies and discussions will proceed during the development of the project. The good news I suppose is that this drug is intended to be used for all Herpe’s class’s of drugs 1-8, has the potential of being a wide spectrum anti-viral I suppose kind of like CMX001. The latest news I have on VN-180 and I’m not sure since it pertains to it, since a lot of it is in Swedish and I do not speak it is on November 13, 2008 :http://www.mynewsdesk.com/se/pressroom/vironova/video/view/vironova-virus-diagnostics-and-antiviral-drug-development-803

 

34. AuRX(HSV-2)(2028): The AuRx herpes therapy is thought to work via cell-mediated immunity (CMI). It is based on accumulating evidence that recurrent disease is associated with a preponderance of immune regulatory T cells [helper type 2 (Th2)] that function to downregulate the ability of the virus specific CMI to control virus replication. The AuRx therapy shifts the balance of the virus specific T cells to a preponderance of protective T cells [helper type 1 (Th1) T cells] and CD8+ killer (cytotoxic) T cells. These cells cause lysis of the virus-infected cells. Soluble mediators are released which produce a response cascade that includes elevated levels of interferon gamma, a stimulator of the Th1 response which also inhibits HSV reactivation from latently infected ganglia. The AuRx therapy also reduces the production of the soluble mediator IL-10 which stimulates production of Th2 cells. Latest news I have is dated September 11, 2006: http://www.aurx.com/pressrelease013.htm

 

35. DR. AMY BUCK(HSV)(2028): This is the latest and only news I have on Amy Buck: Thank you for the interest in our work. We are studying this at multiple levels - but not at the stage of clinical
trials yet. I think in general the host-targeted therapies could have important

implications for treating viral infection, but we have to be rigorous about
knowing how use them properly so there are not non-specific effects.
Sorry to be vague at this stage - it's hard to estimate how long until this
will pay off in terms of a therapy, not in the next 5 years but hopefully
thereafter. Best wishes, AmyBuck (this is from HC MEMBER fruityloopz)


36. AstraZeneca (Motavizumab)(2028)- Is a Monoclonal antibody, it is currently in a Phase III trial. It was intended for treatment and ability to seek out HSV in some studies, HC Member Sweet7 Stated: “It was mentioned on their website at one time that they plan to test it on HSV eventually.” But has now been restricted to treat various RSV. Some of the studies AstraZeneca did they have voluntarily withdrawn from FDA licensing. Latest news was December 2010, not very promising news, but AstraZeneca has the money to back up almost any research: http://en.wikipedia.org/wiki/Motavizumab

 

37. University of Rhode Island(HSV)(2028): Was involved in a Genital Herpes vaccine trial, which has since finished, the results are unknown. The latest news I have dated unknown date :http://www.uri.edu/health/clinical_trials/currentstudies.html 
 
 
38. CYTOGENIX (Simplivir)(2030) – Is a topical cream that works a little differently by that it attacks and cancels the reproduction of the virus and supposedly keep it from migrating to nerve cells. This company has an interesting approach, but I think it will be a while before anything new develops. They claim of a hundred fold decrease in viral load in rats. Latest news I’m aware of was on March 2, 2005, Although they did apply for a patent in 2008 that I did not link to(since it has no viable info):http://www.cytogenix.com/en_us/Company/pr_simplivir.html  (WEBSITE IS CURRENTLY DOWN)

 

 
If you would like to a join a secret facebook group regarding HSV cure research, simply send me an email to : wwdamron1@gmail.com
 
 
 
 
IF YOU HAVE ANY INFO ON THESE OR ANY OTHER DRUGS PLEASE EMAIL ME WITH PROOF AND I MAY ADD A COMMENT BELOW, YOUR NAME CAN REMAIN ANONYMOUS AND I PROMISE YOUR EMAIL AS WELL WILL BE TOO at

 

 

title

Click to add text, images, and other content